Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $110 from $88 and keeps a Buy rating on the shares. 2026 is expected to be a key year for Protagonist Therapeutics, with rusfertide expected to be under regulatory review, ico approval in PsO expected, and potential upside from pipeline progress, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Takeda, Protagonist Therapeutics submit rusfertide new drug application to FDA
- Protagonist Therapeutics price target raised to $108 from $88 at Barclays
- Promising Clinical Data and Strategic Collaborations Drive Buy Rating for Protagonist Therapeutics
- Protagonist Therapeutics price target raised to $115 from $98 at Citi
- Protagonist, Takeda present longer-term data at ASH 2025 on rusfertide